• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Bactroban Nasal
    / GSK

    Active Ingredient
    Mupirocin (as calcium) 2% w/w

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    3 g

    partial basket chart 20801 2371


    Adults (including the elderly/renally impaired/hepatically impaired) and children: Apply a small quantity of Mupirocin nasal ointment, about the size of a match head (approximately 30 mg of ointment) to each nostril twice a day for at least 5 days.
    Method of Administration: Use a cotton tipped applicator. After application, the nostrils should be closed by pressing the sides of the nose together several times.
    Nasal carriage should normally be clear within three to five days of treatment. Dosage should not exceed ten days.
    Do not mix with other preparations as there is a risk of dilution, resulting in a
    reduction in the antibacterial activity and potential loss of stability of the mupirocin in the ointment.


    The elimination of nasal carriage of staphylococci, including methicillin resistant Staphylococcus aureus (MRSA).


    Hypersensitivity to mupirocin or any of the excipients.

    Special Precautions

    Should a possible sensitisation reaction or severe local irritation occur with the use of Bactroban Nasal Ointment, treatment should be discontinued, the product should be wiped away and appropriate therapy instituted.
    As with other antibacterial products, prolonged use may result in overgrowth of non-susceptible organisms.
    Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhea during or after antibiotic use. Although this is less likely to occur with topically applied mupirocin, if prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.
    This mupirocin nasal ointment formulation is not suitable for ophthalmic use.
    Avoid contact with the eyes. If contaminated, the eyes should be thoroughly irrigated with water until the ointment residues have been removed.

    Side Effects

    Immune system disorders: Very rare: Cutaneous hypersensitivity reactions. Systemic allergic reactions such as anaphylaxis, generalised rash, urticaria and angioedema.
    Respiratory, thoracic and mediastinal disorders: Uncommon: Nasal mucosa reactions.
    See prescribing information for full details.

    Drug interactions

    No drug interactions have been identified.

    Pregnancy and Lactation

    Pregnancy: Reproduction studies on Bactroban in animals have revealed no evidence of harm to the foetus. As there is no clinical experience on its use during pregnancy, Bactroban should only be used in pregnancy when the potential benefits outweigh the possible risks of treatment.
    Breast-feeding: There is no information on the excretion of Bactroban in milk.


    Symptoms and signs: There is currently limited experience with overdosage of mupirocin.
    Treatment: There is no specific treatment for an overdose of mupirocin. In the event of overdose, the patient should be treated supportively with appropriate monitoring as necessary.
    Further management should be as clinically indicated or as recommended by the national poisons centre, where available.

    Important notes

    Storage: Store below 25°C.

    Glaxo Operations UK Ltd